Blar i forfatter "Hellesnes, Ragnhild"

Viser treff 1-3 av 3

    • Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era 

      Hellesnes, Ragnhild; Kvammen, Øivind; Myklebust, Tor Åge; Bremnes, Roy M.; Karlsdottir, Åsa; Negaard, Helene Francisca Stigter; Tandstad, Torgrim; Wilsgaard, Tom; Fosså, Sophie Dorothea; Haugnes, Hege Sagstuen (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-10-09)
      Using complete information on total treatment burden, this population‐based study aimed to investigate second cancer (SC) risk in testicular cancer survivors (TCS) treated in the cisplatin era. The Cancer Registry of Norway identified 5,625 1‐year TCS diagnosed 1980–2009. Standardized incidence ratios (SIRs) were calculated to evaluate the total and site‐specific incidence of SC compared to the ...

    • Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study 

      Hellesnes, Ragnhild; Myklebust, Tor Åge; Bremnes, Roy M.; Karlsdottir, Åsa; Kvammen, Øivind; Negaard, Helene Francisca Stigter; Tandstad, Torgrim; Wilsgaard, Tom; Fosså, Sophie Dorothea; Haugnes, Hege Sagstuen (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-12-23)
      PURPOSE - It is hypothesized that cisplatin-based chemotherapy (CBCT) reduces the occurrence of metachronous contralateral (second) germ cell testicular cancer (TC). However, studies including treatment details are lacking. The aim of this study was to assess the second TC risk, emphasizing the impact of previous TC treatment.<p> <p>PATIENTS AND METHODS - Based on the Cancer Registry of Norway, ...

    • Testicular cancer survivors in the cisplatin era: Metachronous contralateral testicular cancer, second cancer and causes of death 

      Hellesnes, Ragnhild (Doctoral thesis; Doktorgradsavhandling, 2021-11-26)
      <p><i>Background/aims:</i> Testicular cancer (TC) is the most common cancer among young men aged 20-40 years. The cure rates are excellent, an important factor being the chemotherapeutic agent cisplatin. This thesis aimed to investigate how TC treatment influenced the subsequent risk for metachronous contralateral (second) TC, non-TC second cancer (SC) and non-TC mortality. <p><i>Methods:</i> The ...